pharmaphorum October 22, 2021

Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna Campbell-Gray.

Consumers are driving and accelerating change when it comes to healthcare, demanding better, faster and more accessible services. The COVID-19 pandemic has further altered the dynamics for this sector and leading players are showing the importance of collaboration, partnership and new forms of innovation in protecting public health globally.

With all eyes on healthcare at the moment, Lundquist conducted a deep dive analysis on Europe’s leading pharmaceutical and biotech companies in...

Today's Sponsors

Qure4u
HLTH
ZeOmega

Today's Sponsors

Premier
TripleTree

Today's Sponsor

Transcarent

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Novo to acquire Dicerna for more than $3B amid RNA drug resurgence
The RNA Moment: Once Second to DNA are Treatments Now Filling the Drug Pipeline
Moderna founder unveils new drug company focused on a different kind of RNA
Small Biotech Outperform Large Pharma in Launch Success
A step towards the development of precision medicine against drug-resistant cancers